Vanguard Group
RPRX icon

Vanguard Group’s Royalty Pharma RPRX Stock Holding History

Vanguard Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$384M Sell
9,934,612
-1,001,926
-9% -$38.2M 0.01% 1207
2025
Q3 		$386M Sell
10,936,538
-25,441,140
-70% -$921M 0.01% 1206
2025
Q2 		$1.31B Sell
36,377,678
-299,770
-0.8% -$9.93M 0.02% 580
2025
Q1 		$1.14B Sell
36,677,448
-676,561
-2% -$21.4M 0.02% 604
2024
Q4 		$953M Sell
37,354,009
-231,114
-0.6% -$6.13M 0.02% 677
2024
Q3 		$1.06B Sell
37,585,123
-437,258
-1% -$12.1M 0.02% 645
2024
Q2 		$1B Buy
38,022,381
+322,699
+0.9% +$8.95M 0.02% 638
2024
Q1 		$1.14B Sell
37,699,682
-297,840
-0.8% -$8.78M 0.02% 603
2023
Q4 		$1.07B Sell
37,997,522
-1,439,832
-4% -$39.6M 0.02% 605
2023
Q3 		$1.07B Buy
39,437,354
+589,558
+2% +$17.5M 0.03% 576
2023
Q2 		$1.19B Buy
38,847,796
+917,777
+2% +$31.1M 0.03% 549
2023
Q1 		$1.37B Buy
37,930,019
+2,302,228
+6% +$85.4M 0.03% 497
2022
Q4 		$1.41B Buy
35,627,791
+675,981
+2% +$28.2M 0.04% 474
2022
Q3 		$1.4B Buy
34,951,810
+2,098,034
+6% +$89.6M 0.04% 449
2022
Q2 		$1.38B Buy
32,853,776
+993,155
+3% +$40.7M 0.04% 479
2022
Q1 		$1.24B Buy
31,860,621
+2,224,056
+8% +$87.3M 0.03% 561
2021
Q4 		$1.18B Sell
29,636,565
-391,497
-1% -$15.2M 0.03% 601
2021
Q3 		$1.09B Buy
30,028,062
+5,685,862
+23% +$221M 0.03% 608
2021
Q2 		$998M Buy
24,342,200
+1,829,607
+8% +$77.8M 0.02% 655
2021
Q1 		$982M Buy
22,512,593
+20,673,627
+1,124% +$980M 0.03% 635
2020
Q4 		$92M Buy
1,838,966
+426,080
+30% +$18.1M ﹤0.01% 1866
2020
Q3 		$59.4M Buy
1,412,886
+29,526
+2% +$1.27M ﹤0.01% 1919
2020
Q2 		$67.2M Buy
+1,383,360
New +$68.5M ﹤0.01% 1856

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Vanguard Group's RPRX Position: Q4 2025 in Review

Vanguard Group reduced its Royalty Pharma (RPRX) stake by 9.2% in Q4 2025, selling an estimated $38.2M and leaving 9,934,612 shares worth $384M. The position accounts for 0.01% of the portfolio, ranked #1207.

Vanguard Group first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $1.41B in Q4 2022. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Vanguard Group held 9,934,612 shares of Royalty Pharma worth $384M as of Q4 2025.
  • Vanguard Group sold 1,001,926 Royalty Pharma shares in Q4 2025, an estimated $38.2M.
  • Royalty Pharma made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1207 holding.
  • Vanguard Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Royalty Pharma position peaked at $1.41B in Q4 2022.
  • 539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.